Rabeprazole Sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318605

CAS#: 117976-90-6

Description: Rabeprazole Sodium Salt is a partially reversible gastric proton pump inhibitor. Rabeprazole Sodium Salt is an inhibitor of ATP4.


Price and Availability

Size
Price

100mg
USD 250
1g
USD 1450
Size
Price

200mg
USD 450
2g
USD 2650
Size
Price

500mg
USD 750
5g
Ask price

Rabeprazole Sodium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318605
Name: Rabeprazole Sodium
CAS#: 117976-90-6
Chemical Formula: C18H20N3NaO3S
Exact Mass:
Molecular Weight: 381.42
Elemental Analysis: C, 56.68; H, 5.29; N, 11.02; Na, 6.03; O, 12.58; S, 8.41


Synonym: Rabeprazole Sodium; Pariet; Aciphex; Rabeprazole sodium salt; Rebeprazole sodium;3810, E; Aciphex; dexrabeprazole; E 3810; E3810; LY 307640; LY-307640; LY307640;

IUPAC/Chemical Name: sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide

InChi Key: KRCQSTCYZUOBHN-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1

SMILES Code: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Tan Y, Si X, Zhong L, Feng X, Yang X, Huang M, Wu C. Development and
validation of dissolution testings in acidic media for rabeprazole sodium
delayed-release capsules. Drug Dev Ind Pharm. 2016 Apr 11:1-9. [Epub ahead of
print] PubMed PMID: 27066697.

2: Sabry SM, Abdel-Hay MH, Belal TS, Mahgoub AA. Development and validation of
HPLC-DAD method for the simultaneous determination of amoxicillin, metronidazole
and rabeprazole sodium. Application to spiked simulated intestinal fluid samples.
Ann Pharm Fr. 2015 Sep;73(5):351-60. doi: 10.1016/j.pharma.2015.04.008. Epub 2015
May 27. PubMed PMID: 26024556.

3: Mohamed HM. A study of selective spectrophotometric methods for simultaneous
determination of Itopride hydrochloride and Rabeprazole sodium binary mixture:
Resolving sever overlapping spectra. Spectrochim Acta A Mol Biomol Spectrosc.
2014 Oct 28;136PC:1308-1315. doi: 10.1016/j.saa.2014.10.018. [Epub ahead of
print] PubMed PMID: 25456673.

4: Ibrahim F, Wahba ME. Liquid chromatography coupled with fluorimetric detection
and third derivative synchronous fluorescence spectroscopy as two analytical
methods for the simultaneous determination of rabeprazole sodium and domperidone
after derivatization with 4-chloro-7-nitrobenzofurazan. J Fluoresc. 2014
Jul;24(4):1137-47. doi: 10.1007/s10895-014-1394-z. Epub 2014 Jun 3. PubMed PMID:
24882601.

5: Swain S, Behera UA, Beg S, Sruti J, Patro ChN, Dinda SC, Rao ME. Design and
characterization of enteric-coated controlled release mucoadhesive microcapsules
of Rabeprazole sodium. Drug Dev Ind Pharm. 2013 Apr;39(4):548-60. doi:
10.3109/03639045.2012.676047. Epub 2012 Apr 18. PubMed PMID: 22512732.

6: Kumar N, Sangeetha D. Development and Validation of a Stability-Indicating
RP-HPLC Method for the Determination of Process-Related Impurities and
Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation. Sci
Pharm. 2013 Mar 17;81(3):697-711. doi: 10.3797/scipharm.1301-25. eCollection
2013. PubMed PMID: 24106668; PubMed Central PMCID: PMC3791934.

7: Nawaz MS. Validation and application of a new reversed phase HPLC method for
in vitro dissolution studies of rabeprazole sodium in delayed-release tablets. J
Anal Methods Chem. 2013;2013:976034. doi: 10.1155/2013/976034. Epub 2013 Aug 22.
PubMed PMID: 24062966; PubMed Central PMCID: PMC3766580.

8: Tirpude RN, Puranik PK. Rabeprazole sodium delayed-release multiparticulates:
Effect of enteric coating layers on product performance. J Adv Pharm Technol Res.
2011 Jul;2(3):184-91. doi: 10.4103/2231-4040.85539. PubMed PMID: 22171316; PubMed
Central PMCID: PMC3217710.

9: Sawant RL, Hadawale SD, Dhikale GK, Bansode CA, Tajane PS. Spectrophotometric
methods for simultaneous estimation of rabeprazole sodium and aceclofenac from
the combined capsule dosage form. Pharm Methods. 2011 Jul;2(3):193-7. doi:
10.4103/2229-4708.90362. PubMed PMID: 23781455; PubMed Central PMCID: PMC3658056.

10: Rao PS, Ray UK, Gupta PB, Rao DV, Islam A, Rajput P, Mukkanti K.
Identification, isolation and characterization of new impurity in rabeprazole
sodium. J Pharm Biomed Anal. 2010 Aug 1;52(4):620-4. doi:
10.1016/j.jpba.2010.01.034. Epub 2010 Jan 25. PubMed PMID: 20153594.

11: Osman AO. Spectrofluorometry, thin layer chromatography, and column
high-performance liquid chromatography determination of rabeprazole sodium in the
presence of its acidic and oxidized degradation products. J AOAC Int. 2009
Sep-Oct;92(5):1373-81. Erratum in: J AOAC Int. 2009 Nov-Dec;92(6):203A. Osman,
Afaf [corrected to Osman, Afaf Osman]; Osman, Mohamed [removed]. PubMed PMID:
19916375.

12: Gandhi SV, Khan SI, Jadhav RT, Jadhav SS, Jadhav GA. High-performance
thin-layer chromatographic determination of rabeprazole sodium and domperidone in
combined dosage form. J AOAC Int. 2009 Jul-Aug;92(4):1064-7. PubMed PMID:
19714973.

13: Ono S, Kato M, Ono Y, Imai A, Yoshida T, Shimizu Y, Asaka M. Immediate
acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium
following initial administration and reintroduction: A randomized, cross-over
study using wireless pH monitoring capsules. J Gastroenterol Hepatol. 2009
Apr;24(4):639-45. doi: 10.1111/j.1440-1746.2008.05644.x. Epub 2008 Nov 20. PubMed
PMID: 19032447.

14: Pillai S, Singhvi I. Quantitative estimation of itopride hydrochloride and
rabeprazole sodium from capsule formulation. Indian J Pharm Sci. 2008
Sep;70(5):658-61. doi: 10.4103/0250-474X.45411. PubMed PMID: 21394269; PubMed
Central PMCID: PMC3038297.

15: Moneeb MS. Chemometric determination of rabeprazole sodium in presence of its
acid induced degradation products using spectrophotometry, polarography and
anodic voltammetry at a glassy carbon electrode. Pak J Pharm Sci. 2008
Jul;21(3):214-24. PubMed PMID: 18614415.

16: Sabnis SS, Dnvandev DN, Jadhav VY, Gandhi SV. Column reversed-phase
high-performance liquid chromatographic method for simultaneous determination of
rabeprazole sodium and domperidone in combined tablet dosage form. J AOAC Int.
2008 Mar-Apr;91(2):344-8. PubMed PMID: 18476346.

17: Mbah CJ. Kinetics of decomposition of rabeprazole sodium in aqueous solutions
determined by high performance liquid chromatography. Pharmazie. 2007
Feb;62(2):112-4. PubMed PMID: 17341029.

18: Garcia CV, Paim CS, Steppe M, Schapoval EE. Development and validation of a
dissolution test for rabeprazole sodium in coated tablets. J Pharm Biomed Anal.
2006 Jun 7;41(3):833-7. Epub 2006 Mar 2. PubMed PMID: 16513316.

19: Pingili RR, Jambula MR, Ganta MR, Ghanta MR, Sajja E, Sundaram V, Boluggdu
VB. Identification and synthesis of potential impurities of rabeprazole sodium.
Pharmazie. 2005 Nov;60(11):814-8. PubMed PMID: 16320941.

20: Garcia CV, Paim CS, Steppe M. New liquid chromatographic method for
determination of rabeprazole sodium in coated tablets. J AOAC Int. 2004
Jul-Aug;87(4):842-6. PubMed PMID: 15295877.